Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04610320
Recruitment Status : Not yet recruiting
First Posted : October 30, 2020
Last Update Posted : October 30, 2020
Sponsor:
Information provided by (Responsible Party):
Ronald Witteles, Stanford University

Brief Summary:
The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If Daratumumab-SC can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

Condition or disease Intervention/treatment Phase
Allosensitization Heart Transplant Failure and Rejection Drug: Daratumumab-SC Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Daratumumab-SC for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation
Estimated Study Start Date : April 1, 2021
Estimated Primary Completion Date : April 1, 2023
Estimated Study Completion Date : April 1, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Daratumumab

Arm Intervention/treatment
Experimental: Daratumumab-SC Injection
  • Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.
  • Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study.
Drug: Daratumumab-SC
>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.




Primary Outcome Measures :
  1. Change in the level of preformed HLA antibodies before and after Daratumumab-SC treatment, based on the absolute difference in PRA levels before and after treatment. [ Time Frame: Baseline and Week 12 (or the last measurement prior to heart transplantation, whichever is earlier). ]
    Will assess the difference in PRA percentage (defined based on those HLA antibodies which have a mean fluorescence intensity [MFI] >3000) at baseline versus Week 12.


Secondary Outcome Measures :
  1. Percent MFI change for each individual preformed HLA antibody at Week 6. [ Time Frame: Baseline and Week 6 (or the last measurement prior to heart transplantation, whichever is earlier). ]
    Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 6 or the time of heart transplantation (whichever is earlier).

  2. Percent MFI change for each individual preformed HLA antibody at Week 12. [ Time Frame: Baseline and Week 12 (or the last measurement prior to heart transplantation, whichever is earlier). ]
    Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 12 or the time of heart transplantation (whichever is earlier).

  3. Percent MFI change for each individual preformed HLA antibody at Week 15. [ Time Frame: Baseline and Week 15 (or the last measurement prior to heart transplantation, whichever is earlier). ]
    Will measure the percent change in the MFI of each circulating preformed HLA antibody from baseline to Week 15 or the time of heart transplantation (whichever is earlier).

  4. Change in the level of preformed HLA antibodies before and after Daratumumab-SC treatment, based on the absolute difference in PRA levels at baseline and Week 6. [ Time Frame: Baseline and Week 6 (or the last measurement prior to heart transplantation, whichever is earlier). ]
    Will assess the difference in PRA percentage (defined based on those HLA antibodies which have a mean fluorescence intensity [MFI] >3000) at baseline versus Week 6.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant is on an active list for a heart transplant.
  • Participant has a high level of allosensitization, defined as a calculated PRA (panel of reactive antibodies) of 50%, based on their antibody status at the time of entry into the study.
  • Ability to understand and willingness to sign an informed consent form prior to any study-related procedures.
  • Women of childbearing potential must have a negative pregnancy test at screening.
  • Both male and female patients must use effective methods of birth control, must not donate eggs or sperm during the course of the study and for 3 months after stopping daratumumab-SC.
  • Adequate bone marrow function.
  • Adequate renal function (estimated GFR greater than or equal to 15 mL/min by the Cockcroft-Gault formula).

Exclusion Criteria:

  • History of allergy or intolerance to daratumumab or Daratumumab-SC.
  • Prior diagnosis of myeloma or light chain amyloidosis.
  • Active infection.
  • Women who are pregnant or breastfeeding.
  • Ongoing desensitization treatment with another agent. Subjects are excluded if they have received:

    • a. IVIG within 30 days of enrollment.
    • b. Proteasome inhibitor within 60 days of enrollment.
    • c. Rituximab within 180 days of enrollment.
  • Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study.
  • Contraindication to herpes zoster prophylaxis.
  • Known to be seropositive for human immunodeficiency virus (HIV).
  • Known to be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
  • Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).
  • Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.
  • Known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
  • Known history of human immunodeficiency virus (HIV).
  • History of blood product transfusion within 60 days of enrollment, or anticipated need for blood product transfusion during the course of the study.
  • Moderate-severe liver dysfunction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04610320


Contacts
Layout table for location contacts
Contact: Stacy Kobayashi 650-723-2805 stacyk@stanford.edu

Sponsors and Collaborators
Ronald Witteles
Investigators
Layout table for investigator information
Principal Investigator: Ronald M Witteles, MD Stanford University
Layout table for additonal information
Responsible Party: Ronald Witteles, Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT04610320    
Other Study ID Numbers: 53476
First Posted: October 30, 2020    Key Record Dates
Last Update Posted: October 30, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ronald Witteles, Stanford University:
Immunotherapy, anti-CD38 antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Daratumumab
Antineoplastic Agents